Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Green Tea Cancer Prevention Claims Offered By FDA Stress Data Limits

This article was originally published in The Tan Sheet

Executive Summary

FDA emphasizes the negative in its specified wording for qualified health claims that may link green tea with prevention of breast and prostate cancers

You may also be interested in...



Qualified Health Claim Study Should Test Letter Grades, SSA Claims – CHPA

FDA should study consumer perceptions of qualified health claims by testing statements that contain both "report card" grades and text ratings, as well as claims that do not bear a letter grade, the Consumer Healthcare Products Association says in recent comments to the agency

Qualified Health Claim Study Should Test Letter Grades, SSA Claims – CHPA

FDA should study consumer perceptions of qualified health claims by testing statements that contain both "report card" grades and text ratings, as well as claims that do not bear a letter grade, the Consumer Healthcare Products Association says in recent comments to the agency

Qualified Health Claim Study Should Test Letter Grades, SSA Claims – CHPA

FDA should study consumer perceptions of qualified health claims by testing statements that contain both "report card" grades and text ratings, as well as claims that do not bear a letter grade, the Consumer Healthcare Products Association says in recent comments to the agency

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS098400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel